Confronting Challenges to Enterotoxigenic Escherichia coli Vaccine Development
Open Access
- 14 September 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Tropical Diseases
- Vol. 2, 709907
- https://doi.org/10.3389/fitd.2021.709907
Abstract
The enterotoxigenic Escherichia coli (ETEC) are a diverse and genetically plastic pathologic variant (pathovar) of E. coli defined by their production of heat-labile (LT) and heat-stable (ST) enterotoxins. These pathogens, which came to recognition more than four decades ago in patients presenting with severe cholera-like diarrhea, are now known to cause hundreds of millions of cases of symptomatic infection annually. Children in low-middle income regions of the world lacking access to clean water and basic sanitation are disproportionately affected by ETEC. In addition to acute diarrheal morbidity, these pathogens remain a significant cause of mortality in children under the age of five years and have also been linked repeatedly to sequelae of childhood malnutrition and growth stunting. Vaccines that could prevent ETEC infections therefore remain a high priority. Despite several decades of effort, a licensed vaccine that protects against the breadth of these pathogens remains an aspirational goal, and the underlying genetic plasticity of E. coli has posed a fundamental challenge to development of a vaccine that can encompass the complete antigenic spectrum of ETEC. Nevertheless, novel strategies that include toxoids, a more complete understanding of ETEC molecular pathogenesis, structural details of target immunogens, and the discovery of more highly conserved antigens essential for virulence should accelerate progress and make a broadly protective vaccine feasible.Keywords
Funding Information
- National Institutes of Health
- National Institutes of Health
- U.S. Department of Veterans Affairs
This publication has 118 references indexed in Scilit:
- The Oral, Live Attenuated Enterotoxigenic Escherichia coli Vaccine ACE527 Reduces the Incidence and Severity of Diarrhea in a Human Challenge Model of Diarrheal DiseaseClinical and Vaccine Immunology, 2012
- Cooperative Role of Antibodies against Heat-Labile Toxin and the EtpA Adhesin in Preventing Toxin Delivery and Intestinal Colonization by Enterotoxigenic Escherichia coliClinical and Vaccine Immunology, 2012
- Nomenclature for Immune Correlates of Protection After VaccinationClinical Infectious Diseases, 2012
- Generation and Characterization of a Live Attenuated Enterotoxigenic Escherichia coli Combination Vaccine Expressing Six Colonization Factors and Heat-Labile Toxin Subunit BClinical and Vaccine Immunology, 2011
- A Combination Vaccine Consisting of Three Live Attenuated Enterotoxigenic Escherichia coli Strains Expressing a Range of Colonization Factors and Heat-Labile Toxin Subunit B Is Well Tolerated and Immunogenic in a Placebo-Controlled Double-Blind Phase I Trial in Healthy AdultsClinical and Vaccine Immunology, 2011
- Proinflammatory T helper type 17 cells are effective B-cell helpersProceedings of the National Academy of Sciences of the United States of America, 2010
- Correlates of Protection Induced by VaccinationClinical and Vaccine Immunology, 2010
- Enterotoxigenic Escherichia coli EtpA mediates adhesion between flagella and host cellsNature, 2008
- The EtpA Exoprotein of Enterotoxigenic Escherichia coli Promotes Intestinal Colonization and Is a Protective Antigen in an Experimental Model of Murine InfectionInfection and Immunity, 2008
- Disease Burden Due to Enterotoxigenic Escherichia coli in the First 2 Years of Life in an Urban Community in BangladeshInfection and Immunity, 2007